<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964388</url>
  </required_header>
  <id_info>
    <org_study_id>UMississippi</org_study_id>
    <nct_id>NCT04964388</nct_id>
  </id_info>
  <brief_title>Effect of GLP-1 Receptor Agonists on Trabecular Bone Score and Visceral Adiposity in Postmenopausal Women With Type 2 Diabetes Mellitus.</brief_title>
  <official_title>Effect of GLP-1 Receptor Agonists on Trabecular Bone Score and Visceral Adiposity in Postmenopausal Women With Type 2 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will help determine the effect of GLP-1 receptor agonists on bone strength in&#xD;
      postmenopausal women with type 2 diabetes mellitus&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postmenopausal women with diabetes mellitus have a higher risk of osteoporotic fractures,&#xD;
      with significant associated mortality and morbidity. Osteoporosis is underdiagnosed in&#xD;
      diabetes, as the bone mineral density (BMD) as currently measured is often normal despite&#xD;
      underlying abnormalities. The trabecular bone score (TBS) is a novel modality to assess bone&#xD;
      microarchitecture and accurately assess fracture risk in patients with diabetes. Due to&#xD;
      increased co-prevalence of osteoporosis and diabetes mellitus, the potential effects of&#xD;
      antidiabetic medications on fracture risk assume importance.&#xD;
&#xD;
      Based on findings in animal studies, we hypothesize that GLP-1 receptor agonists increase TBS&#xD;
      in postmenopausal women with type 2 diabetes mellitus (T2DM). We propose a prospective&#xD;
      non-randomized study by enrolling 48 patients (24 in the GLP group and 24 in the non-GLP&#xD;
      group). DXA scans, markers of bone formation, and resorption, and selected inflammatory&#xD;
      markers will be assessed at baseline, six months, and one year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Trabecular bone score</measure>
    <time_frame>12 months after index date</time_frame>
    <description>The change in TBS from baseline to six months and one year after the initiation of a GLP-1 receptor agonist. TBS will be assessed by DXA scans done at baseline, six months and one year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers and Bone resorption markers</measure>
    <time_frame>12 months after index date</time_frame>
    <description>The change in inflammatory markers (IL-1, IL-6 and TNF-alpha) and bone resorption markers (C-telopeptide) at 6 and 12 months after starting GLP-1 receptor agonists as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral fat mass</measure>
    <time_frame>12 months after index date</time_frame>
    <description>The change in visceral fat mass (measured by DXA) at 6 and 1 year after starting GLP-1 receptor agonists as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sclerostin and Bone formation markers</measure>
    <time_frame>12 months after index date</time_frame>
    <description>The change in levels of sclerostin, osteocalcin, and P1NP (as measured by commercial assays) from baseline to six months and one year after starting GLP-1 receptor agonist.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>GLP-1 cohort</arm_group_label>
    <description>Participants on GLP-1 receptor agonists</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non GLP-1 cohort</arm_group_label>
    <description>Participants not on GLP-1 receptor agonists</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 receptor agonist</intervention_name>
    <description>Diabetes medication</description>
    <arm_group_label>GLP-1 cohort</arm_group_label>
    <arm_group_label>Non GLP-1 cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Post menopausal female patients with Type 2 diabetes mellitus&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Type 2 Diabetes Mellitus&#xD;
&#xD;
          -  Postmenopausal female&#xD;
&#xD;
          -  Age &gt;55 years&#xD;
&#xD;
          -  Hemoglobin A1c between 7-10% within 6 months of the first visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with type 1 Diabetes mellitus&#xD;
&#xD;
          -  Patients with a history of GLP-1 receptor agonist/DPP4 inhibitor use&#xD;
&#xD;
          -  eGFR &lt;30 ml/min in the last 3 months&#xD;
&#xD;
          -  Patients with a history of pancreatitis&#xD;
&#xD;
          -  Personal or family history of medullary thyroid cancer&#xD;
&#xD;
          -  Patients with a history of treatment with anti-osteoporosis agents&#xD;
&#xD;
          -  Documented secondary osteoporosis&#xD;
&#xD;
          -  Documented presence of prosthesis or devices in the spine&#xD;
&#xD;
          -  Unwilling or unable to consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal females</gender_description>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

